Caroline Baumal, MD
Uveitis and Ocular Inflammatory Disease · Boston, MANPI 1891759106
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2022 at $334,915 and has fallen 99.7% since, to $1,090 in 2025.
Across 586 payments — averaging $1405.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$177K
- Novartis$128K
- Regeneron Healthcare Solutions, Inc.$125K
- Apellis Pharmaceuticals, Inc.$116K
- Genentech, Inc.$81K
- Alcon$40K
- plus $158K from 22 others
Across 87 payments — averaging $13,857 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$864K
- Apellis Pharmaceuticals, Inc.$277K
- Regeneron$47K
- F. Hoffmann-la Roche AG$18K
What the payments were for
- Consulting fees$315,96438%
- Speaking & faculty fees$425,62052%
- Travel & lodging$63,3708%
- Food & beverage$18,9452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 114 | $176,980 |
| Novartis | 85 | $127,659 |
| Regeneron Healthcare Solutions, Inc. | 64 | $124,917 |
| Apellis Pharmaceuticals, Inc. | 89 | $116,210 |
| Genentech, Inc. | 52 | $80,602 |
| Alcon | 54 | $39,623 |
| Novartis Pharma AG | 5 | $33,748 |
| F. Hoffmann-la Roche AG | 10 | $26,726 |
| Eyepoint US, Inc. | 20 | $23,800 |
| Carl Zeiss Meditec, Inc. | 17 | $18,103 |
| AbbVie(2 entities) | 27 | $15,865 |
| Dutch Ophthalmic, USA | 9 | $11,637 |
| Regeneron | 5 | $7,537 |
| Thrombogenics, Inc. | 2 | $6,250 |
| Alcon Research LLC | 6 | $4,592 |
| Bausch & Lomb Americas Inc. | 8 | $4,040 |
| Biogen | 2 | $2,831 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $1,545 |
| Topcon Healthcare, Inc. | 1 | $252 |
| Neurotech Pharmaceuticals, Inc. | 1 | $234 |
| Alimera Sciences, Inc. | 4 | $186 |
| Carl Zeiss Meditec USA, Inc. | 1 | $131 |
| Dompe US, Inc. | 1 | $120 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| Tarsus Pharmaceuticals, Inc. | 2 | $61 |
| Boehringer Ingelheim | 1 | $56 |
| Amgen | 1 | $53 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$131,665
- VABYSMO$90,944
- BEOVU$90,726
- Lucentis$87,334
- Constellation$26,769
- YUTIQ$23,408
- OZURDEX$14,278
- EVA, combined machine$10,512
- CLARUS 500$9,100
- Retina Workplace$9,100
- CIRRUS HD-OCT$9,065
- Non-Covered Product$8,947
- Humphrey HFA$8,050
- ARGOS$6,415
- Jetrea$6,250
- Glaucoma Workplace$5,850
- CIRRUS 6000$4,550
- CLARUS$4,517
- XIPERE$3,413
- CIRRUS 5000 with AngioPlex$2,600
How this compares
Too few uveitis and ocular inflammatory disease providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 13 | $4,019 |
Paid to pharmacies, not to this prescriber.
Other uveitis and ocular inflammatory disease in Boston
- Elias ReichelBoston$674K
- Nadia WaheedBoston$346K
- Lana RifkinBoston$77K
- Jay DukerBoston$22K
- Andrew TyeBoston$918
- Sarkis SoukiasianBurlington$196
- Arnold KrollMilford$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.